Challenges for Effective Glycemic control in T2DM during Covid-19 pandemic and Use of Glimepiride/Metformin FDC: Opinion from Indian Clinicians

Dr. Alka Gandhi¹, Dr. C R Anand Moses², Dr. Nilesh Detroja³, Dr. Ajay Ajmani⁴, Dr. Mahesh Abhyankar⁵, Dr. Silki⁵

¹Aayushi Clinic, Mumbai, Maharashtra, India; ²Moses Diabetes and Medical Centre, Chennai, Tamilnadu, India; ³Harmony Super Speciality Hospital, Rajkot,

Guiarat, India: 4BL Kanur Super Speciality Hospital, New Delhi, India: 5USV Private Ltd., Mumbai, Maharashtra, India

Challenges to diabetes management during the COVID-19 pandemic

Background and Objective

Covid-1

structured

descriptively

and mortality, and choice of antidiabetic therapy is

crucial for achieving it. This survey aimed to

understand the perspective of clinicians on Glimepiride/Metformin (Glime/Met) FDC for the

management of Indian T2DM patients during

Methods

administered to 153 clinicians across India via

google forms and the responses were analyzed

Results

obiective

Effective glycemic control is associated reduced risk of Covid-19 severity, complications

Clinicians also opined that patient education, stock

was

reminders.

keeping of medicines for 2-3 months, patient and

cost-effective

therapies

■ Safe prescription alongwith

3).

range: 80% of the clinicians agreed that Glime+Met

FDC is preferred as a safe prescription for T2DM

21.60%

■ Increasing dose of Glimepiride

■ Increasing dose of Metformin

■ Increasing dose of Glime/met

Adding Insulin or new OAD

Figure 3

Glime+Met FDC use across hyperglycemia and age

across spectrum of hyperglycemia and age.

Treatment preference for patients uncontrolled on Glime+Met FDC: A majority of clinicians opined in

favor (Treatment approach for patients uncontrolled on Glime/Met FDC Figure 18.30% 7.20%

52.90%

Conclusion

- Treatment adherence, and availability of effective and safe medications are crucial in achieving optimal glycemic control in T2DM.
- Clinicians consider Glime+Met FDC as a therapy of choice owing to its clinical efficacy, safety,



FDC is preferred owing to its good antihyperglycemic efficacy (Figure 2) Reasons for Clinician preference of Glime/Met FDC 20.3 ■ Good glycemic control ■ Weight neutrality Less hypoglycemia risk

Causes of Uncontrolled glycemia during Covid-19 pandemic: Clinicians reported the lack of physical stress as and the top reasons for uncontrolled glycemia during the Covid-19

pandemic. Challenges in managing diabetes during the Covid-19 pandemic: In-clinic consultation and adherence

questionnaire

insulin and other OADs 75.2 ■ All of the above Figure 2